DCM
FATE icon

DAFNA Capital Management’s Fate Therapeutics FATE Stock Holding History

DAFNA Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Sell
525,000
-25,000
-5% -$46.3K 0.27% 57
2026
Q1 		$660K Hold
550,000
– – 0.15% 68
2025
Q4 		$540K Buy
+550,000
New +$660K 0.13% 68
2023
Q1 		– Sell
-550,940
Closed -$5.56M – 77
2022
Q4 		$5.56M Buy
550,940
+11,000
+2% +$207K 1.57% 19
2022
Q3 		$12.1M Sell
539,940
-11,000
-2% -$318K 3.25% 8
2022
Q2 		$13.7M Buy
550,940
+50,010
+10% +$1.38M 3.72% 5
2022
Q1 		$19.4M Buy
500,930
+128,770
+35% +$4.99M 5.06% 3
2021
Q4 		$21.8M Buy
372,160
+27,800
+8% +$1.58M 5.48% 3
2021
Q3 		$20.4M Buy
344,360
+30,000
+10% +$2.35M 5.41% 3
2021
Q2 		$27.3M Hold
314,360
– – 5.71% 2
2021
Q1 		$25.9M Sell
314,360
-20,000
-6% -$1.92M 6.15% 2
2020
Q4 		$30.4M Sell
334,360
-104,100
-24% -$6.46M 9.05% 2
2020
Q3 		$17.5M Sell
438,460
-52,401
-11% -$1.83M 5.7% 4
2020
Q2 		$16.8M Buy
490,861
+20,861
+4% +$622K 4.86% 3
2020
Q1 		$10.4M Hold
470,000
– – 4.36% 3
2019
Q4 		$9.2M Hold
470,000
– – 3.16% 7
2019
Q3 		$7.3M Buy
470,000
+409,969
+683% +$7.86M 2.75% 7
2019
Q2 		$1.22M Buy
+60,031
New +$1.08M 0.46% 54
2015
Q2 		– Sell
-20,190
Closed -$99K – 79
2015
Q1 		$99K Sell
20,190
-38,920
-66% -$193K 0.08% 67
2014
Q4 		$297K Sell
59,110
-16,820
-22% -$74.2K 0.23% 51
2014
Q3 		$387K Hold
75,930
– – 0.39% 41
2014
Q2 		$479K Buy
+75,930
New +$535K 0.45% 33

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DAFNA Capital Management's FATE Position: Q2 2026 in Review

DAFNA Capital Management reduced its Fate Therapeutics (FATE) stake by 4.5% in Q2 2026, selling an estimated $46.3K and leaving 525,000 shares worth $1.42M. The position accounts for 0.27% of the portfolio, ranked #57.

DAFNA Capital Management first reported a position in FATE in Q2 2014 and has held it in 22 quarters since. The position peaked at $30.4M in Q4 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • DAFNA Capital Management held 525,000 shares of Fate Therapeutics worth $1.42M as of Q2 2026.
  • DAFNA Capital Management sold 25,000 Fate Therapeutics shares in Q2 2026, an estimated $46.3K.
  • Fate Therapeutics made up 0.27% of DAFNA Capital Management's portfolio in Q2 2026, its #57 holding.
  • DAFNA Capital Management first reported a position in Fate Therapeutics in Q2 2014 and has held it in 22 quarters since.
  • DAFNA Capital Management's Fate Therapeutics position peaked at $30.4M in Q4 2020.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.